Blackhawk Growth’s MindBio Therapeutics Successfully Progressed to the Second Half of their Phase 1 Microdosing Clinical Trial
Vancouver, British Columbia – TheNewswire – October 04, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary, MindBio Therapeutics, has successfully progressed to the second half of their fully funded Phase 1 clinical trial microdosing LSD to patients – this is the largest and first safety study of its kind anywhere in the world. The progress in its clinical trials makes MindBio a step closer towards commercialization and bringing new therapies to market.
The clinical trials have been approved by the New Zealand Government who also contributed NZ$600,000 in funding to support this important safety study. Furthermore, the Government of New Zealand has provided an import license and approval for the substances to be administered at home. It is the first clinic trial of its kind in the world that tests microdosing of 80 participants with psychedelics in a community setting.
MindBio is developing into a multi-disciplinary psychedelics platform conducting clinical trials and drug formulation, and technology development through its agreement with Digital Mind Technology and psychedelic assisted therapies with LeichtMind clinics that is also owned by Blackhawk.
“These clinical trials are a first of their kind, anywhere in the world and are unique because of the fact that the New Zealand Government has given approval for LSD to be imported, experimented with in a laboratory and for a doctor to prescribe LSD in microdoses for patients to take at home as they would any other medication” says Frederick Pels, CEO of Blackhawk Growth Corp. “We are very pleased that the clinical trials have completed their first half and are progressing towards the finish line within budget and timeframes. We look forward to updating our shareholders in the coming weeks.”
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.